| 1. |
Snoeck E, Stockis A. Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res, 2007, 73(3): 284-291.
|
| 2. |
Fang Y, Wu X, Xu L, et al. Randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types. J Clin Neurosci, 2014, 21(1): 55-62.
|
| 3. |
Kwon OY, Park SP. Depression and anxiety in people with epilepsy. J Clin Neurol, 2014, 10(3): 175-188.
|
| 4. |
Kanner AM, Barry JJ, Gilliam F, et al. Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy?. Epilepsia, 2010, 51(7): 1152-1158.
|
| 5. |
Gandy M, Sharpe L, Perry KN, et al. Rates of DSM-Ⅳ mood, anxiety disorders, and suicidality in Australian adult epilepsy outpatients: a comparison of well-controlled versus refractory epilepsy. Epilepsy Behav, 2013, 26(1): 29-35.
|
| 6. |
Salgado PC, Yasuda CL, Cendes F. Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression. Epilepsy Behav, 2010, 19(3): 422-427.
|
| 7. |
Panayiotis N, Varelas, Corry J, et al. Management of status epilepticus in neurologicalversus medical intensive care unit: does it matter?. Neurocrit Care, 2013, 19(1): 4-9.
|
| 8. |
James J, Riviello J, Claassen J, et al. The neurocritical care society status epilepticus guideline writing committee. Treatment of status epilepticus: an international survey of experts. Neurocrit Care, 2013, 18(2): 193-200.
|
| 9. |
Westbrook GL, Lothman EW. Cellular and synaptic basis of kainic acid-induced hippocampal epileptiform activity. Brain Res, 1983, 273(1): 97-109.
|
| 10. |
Gupta V, Yesilbursa D, Huang WY, et al. Patent foramen ovale in a large population of ischemic stroke patients: diagnosis, age distribution, gender, and race. Echocardiography, 2008, 25(2): 217-227.
|
| 11. |
Hara H, Virmani R, Ladich E, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol, 2005, 46(9): 1768-1776.
|
| 12. |
Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med, 2013, 368(12): 1092-1100.
|
| 13. |
Yanagawa Y, Yoshihara T, Kato H, et al. Significance of urinary incontinence, age, and consciousness level on arrival among patients with stroke. J Emerg Trauma Shock, 2013, 6(2): 83-86.
|
| 14. |
王娟, 潘速躍, 王靜新, 等. 腦卒中后尿失禁近期預后的影響因素. 中國老年學雜志, 2015, 35(20): 5789-5791.
|
| 15. |
Nakayama H, J?rgensen HS, Pedersen PM, et al. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke, 1997, 28(1): 58-62.
|
